Sterling Capital Management’s Candel Therapeutics CADL Stock Holding History
Bought
Maintained
Sold
Other funds holding CADL
ACA
SVCM
Sterling Capital Management's CADL Position: Q3 2026 in Review
Sterling Capital Management increased its Candel Therapeutics (CADL) stake by 540% in Q3 2026, buying an estimated $19.8K and bringing the position to 2,119 shares worth $22.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2145.
Sterling Capital Management first reported a position in CADL in Q3 2024 and has held it in 9 quarters since. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.
- Sterling Capital Management held 2,119 shares of Candel Therapeutics worth $22.1K as of Q3 2026.
- Sterling Capital Management bought 1,788 Candel Therapeutics shares in Q3 2026, an estimated $19.8K.
- Candel Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2145 holding.
- Sterling Capital Management first reported a position in Candel Therapeutics in Q3 2024 and has held it in 9 quarters since.
- 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.
Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.